{{Drugbox
| IUPAC_name        = ''N''-[7-Isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1''H''-quinazolin-3-yl]methanesulfonamide
| image             = Selurampanel.svg
| CAS_number        = 912574-69-7 
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 45381907
| DrugBank          = 
| ChemSpiderID      = 32698379
| C=16 | H=19 | N=5 | O=4 | S=1
| molecular_weight  = 377.418 g/mol
| smiles            = CC(C)c1cc2c(cc1c3ccnn3C)c(=O)n(c(=O)[nH]2)NS(=O)(=O)C
| StdInChI          = 1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23)
| StdInChIKey       = MCECSFFXUPEPDB-UHFFFAOYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Selurampanel''' ([[International Nonproprietary Name|INN]], code name '''BGG492''') is a [[drug]] closely related to the [[quinoxalinedione]] series which acts as a [[competitive antagonist]] of the [[AMPA receptor|AMPA]] and [[kainate receptor]]s and, as of 2015, is being investigated in [[clinical trial]]s by [[Novartis]] for the treatment of [[epilepsy]].<ref name="Faught2014">{{cite journal|last1=Faught|first1=Edward|title=BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy|journal=Expert Opinion on Investigational Drugs|volume=23|issue=1|year=2014|pages=107–113|issn=1354-3784|doi=10.1517/13543784.2014.848854}}</ref><ref name="BelcastroVerrotti2015">{{cite journal|last1=Belcastro|first1=Vincenzo|last2=Verrotti|first2=Alberto|title=Novel Molecular Targets for Drug-Treatment of Epilepsy|year=2015|pages=183–199|doi=10.1007/978-3-319-12283-0_10}}</ref><ref name="Hanada2014">{{cite journal|last1=Hanada|first1=Takahisa|title=The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence|journal=Journal of Receptor, Ligand and Channel Research|year=2014|pages=39|issn=1178-699X|doi=10.2147/JRLCR.S51475}}</ref> It has also been studied in the acute treatment of [[migraine]], and was found to produce some pain relief, but with a relatively high rate of [[side effect]]s.<ref name="pmid23963355">{{cite journal  |vauthors=Gomez-Mancilla B, Brand R, Jürgens TP, etal | title = Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks | journal = Cephalalgia | volume = 34 | issue = 2 | pages = 103–13 |date=February 2014  | pmid = 23963355 | doi = 10.1177/0333102413499648 | url = http://cep.sagepub.com/cgi/pmidlookup?view=long&pmid=23963355}}</ref>

==References==
{{Reflist|2}}


{{Anticonvulsants}}
{{Antimigraine preparations}}
{{Ionotropic glutamate receptor modulators}}

[[Category:AMPA receptor antagonists]]
[[Category:Anticonvulsants]]
[[Category:Antimigraine drugs]]
[[Category:Kainate receptor antagonists]]
[[Category:Pyrazoles]]
[[Category:Quinazolines]]
[[Category:Sulfonamides]]


{{nervous-system-drug-stub}}